LEUVEN, Belgium, July 2, 2024
/PRNewswire/ -- P95 BV ("P95"), a global leader in
clinical and epidemiology research solutions, with a focus on
vaccines and infectious diseases, is excited to announce the
strategic acquisition of 4Clinics, a Contract Research Organization
(CRO) providing Data Management, Biostatistics, Scientific Writing,
Regulatory Affairs and Clinical Operations services for clinical
and epidemiological studies with expertise in vaccines,
immunotherapeutics and medical devices. P95 is a portfolio
company of private equity firm Ampersand Capital Partners
("Ampersand"). Commencing on 1 July
2024, the 4Clinic's team and operations will be fully
integrated into the P95 group.
Thomas Verstraeten, CEO of P95,
comments, "I am very excited to have the 4Clinics team as part of
the P95 group. 4Clinics has a long history of supporting a wide
range of customers across the globe, and like us, is well known for
its expertise in vaccines and infectious disease. The knowledge and
experience they bring, particularly in biometrics and medical
writing, will significantly strengthen our capacity and enhance our
ability to provide full-scale CRO services to our customers.
Establishing ourselves in France
will also enable us to better serve our Francophone
clientele."
The President of 4Clinics, Fabrice Degrez remarks, "We
are thrilled to start this strategic partnership in a competitive
market where consolidation is key. By joining forces with P95, a
like-minded partner sharing our Belgian roots, we are setting a
robust foundation for innovation and enhanced capabilities. This
collaboration underscores our commitment to excellence and ensures
continuity and improved services for our customers. Together, we
are dedicated to sustaining long-term advancements in our
field."
"Under P95's leadership, numerous strategic programs have been
initiated, showcasing impressive progress towards building a
leading Infectious Disease & Vaccine CRO with both
observational and clinical capabilities. Ampersand is proud to
support a company that significantly contributes to improving
access to life-saving drugs and medicines for patients worldwide,"
adds Benoit Bouche, Board Chairman
of P95 and Ampersand Operating Partner.
About P95
P95, an Ampersand portfolio company, is a leading global
provider of clinical and epidemiology research solutions with a
specialty focus on vaccines and infectious diseases. With
headquarters in Belgium, and
regional hubs in Africa
(South Africa), Latin America (Colombia), North
America (USA), and
Southeast Asia (Thailand), P95's full-service CRO solutions
span across 5 continents with staff in over 25 countries. P95
offers a wide range of solutions including phase I-IV clinical
studies, epidemiology, and RWE studies, in addition to scientific
and clinical development consulting, P95 provides end-to-end
services including study start-up, clinical monitoring, sample
management, medical monitoring and pharmacovigilance, qualitative
research, medical writing, data management, biostatistics, and
IT.
About 4Clinics
4Clinics is a Contract Research Organization (CRO)
providing Data Management, Biostatistics, Scientific Writing,
Regulatory Affairs and Clinical Operations services for clinical
and epidemiological studies with a particular expertise in
vaccines, immunotherapeutics and medical devices. 4Clinics
serves pharmaceutical, biotechnology and medical devices companies
as well as NGOs, hospitals and researchers with tailor-made
services including remote biometry and medical writing platforms.
4Clinics has offices in Belgium,
France, and Morocco.
About Ampersand Capital Partners
Founded in 1988, Ampersand Capital Partners
is a middle market private equity firm with $3 billion of assets under management dedicated
to growth-oriented investments in the healthcare sector. With
offices in Boston, MA and
Amsterdam, Netherlands, Ampersand
leverages a unique blend of private equity and operating experience
to build value and drive long-term performance alongside its
portfolio company management teams. Ampersand has helped build
numerous market-leading companies across each of the firm's core
healthcare sectors. For additional information,
visit ampersandcapital.com
or follow us on
LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/p95-acquires-4clinics-to-expand-global-cro-services-strengthen-position-as-market-leader-302188157.html
SOURCE P95 BV